ICCS 2013 - Portfolio
|
|
“The ICCS was a great start to Bio2013, it was interesting to see the other cancer companies present and we made a few excellent contacts that otherwise we may not have connected with. I will certainly be present at ICCS 2014.”
Richard Godfrey, CEO, BerGenBio |
|
|
|
|
|
|
“We are at a development stage where we need to communicate what we are doing. It is impossible to have an overview over all possibilities for scientific sensible co-development. Participating at ICCS 2013 and presenting our project gave us the possibility to inform possible development partners in a way that makes it possible for them to see possible synergies with us.” Øyvind Arnesen, CEO, Ultimovacs |
|
|
|
|
“Cancer Research Technology presented an immunotherapy spinout from the University of Birmingham at the 2013 ICCS event, and as
a result are now following up with two independent investors who expressed serious interest in the company.”
Andrea Schivella, Cancer Research Technology |
|
|
“I think the ICCS event was good. It gave us a number of contacts that seems valuable for further follow-up. I think the format also works well.” Odd Arild Lehne, CEO, PubGene |
Photos by: anthony@lapennaphotography.com